source
- Kyverna Therapeutics reports encouraging data for first CAR-T therapy targeting autoimmune diseaseKyverna Therapeutics released new data that strengthens its case for bringing the first CAR‑T treatment for an autoimmune condition to market. The results come after recent safety setbacks in simil…
- Roivant Sciences launches first solo drug, Lisraya, after FDA approval for dermatomyositisRoivant Sciences, which operates a hub-and-spoke subsidiary model, is stepping into the commercial arena with its inaugural solo product launch. The FDA has granted approval to the oral TYK2/JAK i…